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A man in his mid-forties (BMI 21.2 kg/m 2 ), originally from the Ivory Coast, presented to the Infectious Diseases Department with headaches, seizures, sensory disorders, weight loss (#12 kg in 6 months) and recent T4-T6 paraplegia. He was diagnosed as HIVpositive in 2001 with 428 CD4/mm 3 and plasma HIV-1-RNA (pVL) at 2750 copies/mL. In 2011, he was initiated on efavirenz/emtricitabine/tenofovir disoproxil fumarate with rapid virological response (pVL ,50 copies/mL) and 920 CD4/mm 3 (42%). On admission, despite undetectable pVL and 594 CD4/mm 3 (30%), meningitis was diagnosed, based on CSF results: protein 4 g/L, normal glycorrhachia and HIV-RNA 69 copies/mL. Neuroimaging confirmed thoracic myelitis and brain biopsy showed meningitis with perivascular CD8! infiltrate (42 cells/mm 3 ). Different serologies (HBV, HCV, toxoplasmosis, TB, syphilis, Lyme disease and Whipple disease) were negative in blood or CSF. Anti-TB probabilistic treatment and steroids were initiated, and were clinically and biologically moderately beneficial after 7 weeks of treatment. At that time, positive galactomannan (1.48), negative b-D-glucan (,32 pg/mL) and positive Histoplasma capsulatum PCR (29 cycle threshold) confirmed diagnosis of cerebral histoplasmosis. Liposomal amphotericin B therapy (6 mg/kg) and itraconazole oral suspension (300 mg q8h then 200 mg q12h) were initiated, but amphotericin B was discontinued after 6 weeks of treatment because of renal impairment (estimated glomerular filtration rate " 42 mL/min). At the same time, efavirenz/ emtricitabine/tenofovir disoproxil fumarate was switched to darunavir/ritonavir, abacavir/lamivudine and maraviroc (600/100 mg q12h, 600/300 mg q24h and 150 mg q12h, respectively).
Measurements of itraconazole and its active hydroxyl metabolite and also antiretroviral trough concentrations (C min ) in plasma and CSF were performed ( Figure 1 ) to assess pharmacokinetic variability, monitor adherence and evaluate potential drug interactions. In the particular case of Histoplasma meningitis, the target of the active sum of itraconazole and hydroxy-itraconazole plasma C min should be at least 2000 lg/L. 1 In our case, the active sum of plasma C min at day 7 was 4-6-fold higher, where darunavir C min was 2-fold higher than in healthy adult volunteers, 2 showing reciprocal drug-drug enzymatic inhibitions. Even with low serum protein levels (21 g/L) and high plasma exposure, itraconazole and hydroxy-itraconazole were both ,25 lg/L in CSF.
During this time, the patient deteriorated, experiencing confusion, drowsiness and severe diarrhoea. To minimize toxicity, itraconazole oral suspension was discontinued after 3 months and darunavir/ritonavir was replaced by dolutegravir (50 mg q24h) with unchanged backbone. One month later, itraconazole and hydroxy-itraconazole C min continued to be monitored and were decreased to normal values: 1030 and 1325 lg/L with elimination half-lives of 5.8 and 9.6 days, respectively (compared with normal half-lives of 1.5 and 3 days) 2 allowing resumption of itraconazole.
A complete inversion of the hydroxy-itraconazole/itraconazole metabolic ratio (describing itraconazole's disposition) was observed from 0.2 to .1.3 with the switch from darunavir/ritonavir to dolutegravir, resulting in the normalization of itraconazole metabolism. The patient's drowsiness decreased and confusion and diarrhoea resolved. After 4 months of itraconazole, results of the search for H. capsulatum DNA were negative in CSF, as well as galactomannan antigen in CSF (0.18). The role of itraconazole in the treatment of cerebral histoplasmosis is still unclear. Its effectiveness is based on an experimental model of Histoplasma meningitis, 3 but it does not penetrate the CSF in vivo. There are case reports of success, but also failure, in using itraconazole for treatment of Histoplasma meningitis. 4 To our knowledge, this is the first case of serious neuropsychiatric adverse effects related to drug-drug interaction between itraconazole and darunavir/ritonavir. Although itraconazole has the best in vitro pharmacodynamic profile, its pharmacokinetic characteristics, particularly its high protein binding, might explain its low penetration in deep sanctuaries such as the cerebral compartment. 5 Moreover, a toxicodynamic relationship was previously reported with more than 40% predicted probability of adverse event for itraconazole C min of 10 000 lg/L. 6 In our case, this C min was easily reached because of enhancement by darunavir/ritonavir. Indeed, itraconazole is a substrate and an inhibitor of both Pglycoprotein and CYP3A4, whereas ritonavir is a strong CYP3A4 inhibitor. 7 Thus, darunavir/ritonavir increases itraconazole plasma exposure by preventing its biotransformation to hydroxy-itraconazole and other metabolites. The switch to dolutegravir promotes the normalization of the hydroxyitraconazole/itraconazole metabolic ratio and the recovery of neurological adverse effects; dolutegravir is a substrate of UDPglucuronosyltransferase 1A1 and CYP3A4, and is neither an inducer nor an inhibitor of CYP3A4 or P-glycoprotein. 8 Despite the theoretical risk of interactions between itraconazole and antiretroviral drugs, there are little data to support recommendations regarding interactions or guide patient management. Current guidelines recommend monitoring of itraconazole C min during concomitant therapy, as well as observing signs and symptoms of toxicities. 9, 10 Neurological side effects are not frequent with itraconazole and azole antifungals, and reports of overdose are scarce in the medical literature. For our patient, the absence of symptoms before itraconazole introduction, the high plasma exposure of itraconazole and the favourable outcome after itraconazole C min normalization strongly support the responsibility of itraconazole. This case highlights the need to use therapeutic drug monitoring and to adapt HIV treatment when associated with antifungals such as azoles.
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Sir, We read with great interest the comprehensive narrative review on antimicrobial resistance in South-East Asia by Zellweger et al.
1
However, the paper did not include any relevant information about Timor-Leste, one of the countries included in the WHO South-East Asia Region. Timor-Leste has one of the lowest incomes per capita in the region 2 and infectious diseases still account for a substantial burden in terms of both morbidity and mortality. 3 While some data are available about TB, malaria and HIV, 3 little is known about antibiotic resistance.
In order to better explore the epidemiology of antibiotic resistance in Timor-Leste, we performed a systematic review of the literature. Using a combination of terms including TimorLeste/East-Timor and antibiotic/antimicrobial resistance, we systematically searched the MEDLINE, Web of Science, Cochrane Library and Scielo databases from inception until 31 October 2017. Moreover, using the same search terms (and manual search where necessary), we screened: web sites of the Timorese Ministry of Health (MoH), the WHO, the Center for Disease Dynamics, Economics & Policy, the CDC, the ECDC, the Australian Government Department of Health and key regional and international infectious diseases societies; Google Scholar; ResearchGate; and two grey literature search engines (see the Supplementary data available at JAC Online). Each step of the process was carried out by one investigator. We only focused on antibiotic resistance, thus antimycobacterial, antiviral and antiparasitic resistance were not considered.
We obtained 916 articles/web documents and selected 30 of them after title and abstract (where available) screening. The full text of these 30 documents was analysed and finally only one WHO publication and three articles were retained. Two of these papers were published in journals indexed on MEDLINE.
In the most recent article, by Conceição et al., 4 167 inpatients and healthcare workers from two hospitals in the capital, Dili, were screened for Staphylococcus aureus nasal carriage in 2010-14. None of the 22 positive patients harboured MRSA; all isolates were penicillin resistant and 21% were tetracycline resistant. Another article by Conceição et al., 5 published in an unindexed journal, appears to report preliminary results of the same study and it shows the same results concerning Timor-Leste. 4 In a different study, by Oliveira et al., 6 skin swab samples were collected in 2006 from 46 Timorese river buffalos in three farms located in a peripheral district (Lospalos). They identified some Gram-positive bacteria of relevance to human medicine, including CoNS, Micrococcus sp. and Rhodococcus sp. They described a discrete prevalence of resistance to b-lactams (methicillin resistance in 33% and 73% of cocci and bacilli, respectively), but data were 
